Compile Data Set for Download or QSAR
Report error Found 128 Enz. Inhib. hit(s) with all data for entry = 8531
TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256239BDBM256239(US9487483, 91)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256272BDBM256272(US9487483, 124)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256178BDBM256178(US9487483, 30)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256259BDBM256259(US9487483, 111)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256246BDBM256246(US9487483, 98)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256269BDBM256269(US9487483, 121)
Affinity DataIC50: 15nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256170BDBM256170(US9487483, 22)
Affinity DataIC50: 15nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256171BDBM256171(US9487483, 23)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256265BDBM256265(US9487483, 117)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256254BDBM256254(US9487483, 106)
Affinity DataIC50: 18nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256208BDBM256208(US9487483, 60)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256153BDBM256153(US9487483, 5)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256263BDBM256263(US9487483, 115)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256187BDBM256187(US9487483, 37)
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256212BDBM256212(US9487483, 64)
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256210BDBM256210(US9487483, 62)
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256243BDBM256243(US9487483, 95)
Affinity DataIC50: 25nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256174BDBM256174(US9487483, 26)
Affinity DataIC50: 26nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256177BDBM256177(US9487483, 29)
Affinity DataIC50: 28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256257BDBM256257(US9487483, 109)
Affinity DataIC50: 28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256173BDBM256173(US9487483, 25)
Affinity DataIC50: 28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256221BDBM256221(US9487483, 73)
Affinity DataIC50: 29nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256197BDBM256197(US9487483, 49)
Affinity DataIC50: 29nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256209BDBM256209(US9487483, 61)
Affinity DataIC50: 32nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256236BDBM256236(US9487483, 88)
Affinity DataIC50: 34nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256251BDBM256251(US9487483, 103)
Affinity DataIC50: 36nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256204BDBM256204(US9487483, 56)
Affinity DataIC50: 37nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256230BDBM256230(US9487483, 82)
Affinity DataIC50: 38nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256213BDBM256213(US9487483, 65)
Affinity DataIC50: 38nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256229BDBM256229(US9487483, 81)
Affinity DataIC50: 39nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256175BDBM256175(US9487483, 27)
Affinity DataIC50: 40nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256206BDBM256206(US9487483, 58)
Affinity DataIC50: 41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256219BDBM256219(US9487483, 71)
Affinity DataIC50: 41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256207BDBM256207(US9487483, 59)
Affinity DataIC50: 43nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256258BDBM256258(US9487483, 110)
Affinity DataIC50: 48nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256211BDBM256211(US9487483, 63)
Affinity DataIC50: 49nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256231BDBM256231(US9487483, 83)
Affinity DataIC50: 50nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256154BDBM256154(US9487483, 6)
Affinity DataIC50: 56nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256202BDBM256202(US9487483, 54)
Affinity DataIC50: 57nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256234BDBM256234(US9487483, 86)
Affinity DataIC50: 58nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256232BDBM256232(US9487483, 84)
Affinity DataIC50: 60nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256180BDBM256180(US9487483, 32)
Affinity DataIC50: 63nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256275BDBM256275(US9487483, 127)
Affinity DataIC50: 80nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256184BDBM256184(US9487483, 39)
Affinity DataIC50: 85nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256244BDBM256244(US9487483, 96)
Affinity DataIC50: 90nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256261BDBM256261(US9487483, 113)
Affinity DataIC50: 90nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256195BDBM256195(US9487483, 47)
Affinity DataIC50: 91nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256241BDBM256241(US9487483, 93)
Affinity DataIC50: 92nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256238BDBM256238(US9487483, 90)
Affinity DataIC50: 95nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 256176BDBM256176(US9487483, 28)
Affinity DataIC50: 100nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: